Lauria, F <br/><br/>
Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.  [electronic resource] 

 -  Bone marrow transplantation  Jul 1996 
 - 79-85 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0268-3369 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic--administration & dosage<br/>Adult<br/>Bone Marrow Transplantation--immunology<br/>Combined Modality Therapy<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Injections, Subcutaneous<br/>Interleukin-2--administration & dosage<br/>Killer Cells, Natural--drug effects<br/>Lymphocyte Subsets--drug effects<br/>Lymphoma, Non-Hodgkin--immunology<br/>Male<br/>Neoplasm, Residual<br/>Receptors, IgG--analysis<br/>Recombinant Proteins--administration & dosage<br/>Remission Induction<br/>T-Lymphocyte Subsets--drug effects